Oculis Holding AG
NasdaqGM:OCS Stock Report
Oculis Holding Dividends and Buybacks
Dividend criteria checks 0/6 Oculis Holding does not have a record of paying a dividend.
Key information Total Shareholder Yield -7.2% Future Dividend Yield 0% Dividend Growth n/a Next dividend pay date n/a Ex dividend date n/a Dividend per share n/a Payout ratio n/a
Recent dividend and buyback updates
Show all updates
Oculis: Lack Of Coverage Only Real Risk For This Solid Company Nov 04
Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer Oct 02
Oculis Holding AG Appoints Sharon Klier as Chief Development Officer Aug 15 Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024
Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy Jun 13
Oculis Holding AG Announces Board and Committee Appointments May 30
First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023) May 09 Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million. May 09
Oculis Holding AG, Annual General Meeting, May 29, 2024 May 01
Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million. Apr 24
Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million. Apr 12
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development Apr 10
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Apr 09
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 20
New major risk - Revenue and earnings growth Mar 20
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Dec 21
Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema Dec 19
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease Dec 08
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 17 Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors Nov 17
Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress Oct 11
Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema Oct 06
New major risk - Revenue and earnings growth Oct 01
Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer Sep 12
Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022) Sep 02
Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops Aug 09
Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases Jun 28
High number of new and inexperienced directors Mar 30
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCS's dividend payments have been increasing.
Dividend Yield vs Market Oculis Holding Dividend Yield vs Market
How does OCS dividend yield compare to the market? Segment Dividend Yield Company (OCS) n/a Market Bottom 25% (US) 1.3% Market Top 25% (US) 4.3% Industry Average (Pharmaceuticals) 2.3% Analyst forecast (OCS) (up to 3 years) 0%
Notable Dividend: Unable to evaluate OCS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate OCS's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OCS has not reported any payouts.
Discover strong dividend paying companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}